{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:24:35Z","timestamp":1786947875416,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12328-026-02375-4","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:40:54Z","timestamp":1781250054000},"page":"1003-1007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage tacrolimus therapy for steroid-refractory immune-related adverse event-associated sclerosing cholangitis"],"prefix":"10.1007","volume":"19","author":[{"given":"Shinya","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7038-7955","authenticated-orcid":false,"given":"Shinya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodai","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kurokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2375_CR1","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","volume":"33","author":"B Pi","year":"2021","unstructured":"Pi B, Wang J, Tong Y, et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol. 2021;33:e858\u201367.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2375_CR2","doi-asserted-by":"crossref","unstructured":"Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 (Supplement 4):iv119\u2013iv42.","DOI":"10.1093\/annonc\/mdx225"},{"key":"2375_CR3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"2375_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","volume":"23","author":"K Reynolds","year":"2018","unstructured":"Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist. 2018;23:991\u20137.","journal-title":"Oncologist"},{"key":"2375_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101619","volume":"28","author":"H Xing","year":"2023","unstructured":"Xing H, Wang Y, Qu B, et al. The current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity. Transl Oncol. 2023;28:101619.","journal-title":"Transl Oncol"},{"key":"2375_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529\u201336.","journal-title":"Invest New Drugs"},{"key":"2375_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353\u201365.","journal-title":"World J Gastroenterol"},{"key":"2375_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5174","volume":"9","author":"K Arai","year":"2021","unstructured":"Arai K, Matsuda M, Nakayasu H, et al. Nivolumab-induced liver injury with a steroid-refractory increase in biliary enzymes, in a patient with malignant mesothelioma: an autopsy case report. Clin Case Rep. 2021;9:e05174.","journal-title":"Clin Case Rep"},{"key":"2375_CR9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"CL Bowlus","year":"2022","unstructured":"Bowlus CL, Lim JK, Lindor KD. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2022;75:1012\u201344.","journal-title":"Hepatology"},{"key":"2375_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/jjco\/hyae060","volume":"54","author":"K Okamoto","year":"2024","unstructured":"Okamoto K, Hijioka S, Nagashio Y, et al. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Jpn J Clin Oncol. 2024;54:887\u201394.","journal-title":"Jpn J Clin Oncol"},{"key":"2375_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025774","volume":"100","author":"Y Hirasawa","year":"2021","unstructured":"Hirasawa Y, Yoshimura K, Matsui H, et al. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore). 2021;100:e25774.","journal-title":"Medicine (Baltimore)"},{"key":"2375_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.37349\/etat.2024.00250","volume":"5","author":"S Gray","year":"2024","unstructured":"Gray S, Santamaria N, Olsson-Brown A. Immune checkpoint inhibitor-induced cholangitis\u2014a three-case series. Explor Target Antitumor Ther. 2024;5:818\u201325.","journal-title":"Explor Target Antitumor Ther"},{"key":"2375_CR13","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/j.jtho.2019.04.023","volume":"14","author":"B Anderson","year":"2019","unstructured":"Anderson B, Dawe DE. Nivolumab-induced secondary sclerosing cholangitis with deterioration despite immunosuppression. J Thorac Oncol. 2019;14:e205\u20136.","journal-title":"J Thorac Oncol"},{"key":"2375_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2217\/imt-2019-0121","volume":"11","author":"CA Reddy","year":"2019","unstructured":"Reddy CA, Schneider BJ, Brackett LM, et al. Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. Immunotherapy. 2019;11:1527\u201331.","journal-title":"Immunotherapy"},{"key":"2375_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138.","journal-title":"JAMA Oncol"},{"key":"2375_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306.","journal-title":"J Immunother Cancer"}],"updated-by":[{"DOI":"10.1007\/s12328-026-02423-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000}}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02375-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:34:34Z","timestamp":1786944874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02375-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2375"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02375-4","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the Table 1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12328-026-02423-z","URL":"https:\/\/doi.org\/10.1007\/s12328-026-02423-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee.","order":2,"name":"Ethics","label":"Human participant and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patient.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}